Sugi Predict
/ Targets
/ BCL6
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to BCL6 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma |
PHASE4 | NOT_YET_RECRUITING |
| Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients |
PHASE3 | UNKNOWN |
| Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
PHASE2 | RECRUITING |
| Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients |
PHASE2 | COMPLETED |
| DALY II Japan/MB-CART2019.1 for DLBCL |
PHASE2 | RECRUITING |
| The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma |
PHASE1/PHASE2 | WITHDRAWN |
| A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression |
PHASE2 | UNKNOWN |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders |
PHASE1/PHASE2 | COMPLETED |
| A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma |
PHASE1/PHASE2 | RECRUITING |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma |
PHASE1/PHASE2 | RECRUITING |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies |
PHASE2 | COMPLETED |
| CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma |
PHASE1/PHASE2 | COMPLETED |
| Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA |
PHASE1 | RECRUITING |
| A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma |
PHASE1 | COMPLETED |
| Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma |
PHASE1 | UNKNOWN |
| A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma |
PHASE1 | COMPLETED |
| Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies |
PHASE1 | ACTIVE_NOT_RECRUITING |
| A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) |
EARLY_PHASE1 | RECRUITING |
| Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma |
nan | NOT_YET_RECRUITING |
| A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma |
nan | RECRUITING |
| Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas |
nan | NOT_YET_RECRUITING |
| BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. |
nan | UNKNOWN |
| Anti CD19 Gene Therapy for B-cell Lymphoma |
nan | RECRUITING |
| Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma |
nan | COMPLETED |
| Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas. |
nan | COMPLETED |
| Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) |
nan | RECRUITING |
| Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma |
nan | RECRUITING |
| Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma |
nan | NOT_YET_RECRUITING |
Related proteins — ESM-2 sequence neighbours (a BCL6 binder may also engage these)